drugset / Trial / NCT04515186
Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World
RandomizedParallel-groupSingle-blindTreatment
Summary
This study evaluates if the combination of thermotherapy (one application, 50⁰C for 30") and 3 weeks of miltefosine is safe and have a comparable cure rate with the current recommended first line treatments comprising meglumine antimoniate for 3 weeks for the treatment of uncomplicated cutaneous leishmaniasis cases in the New World.
Timeline
- Start
- 2021-01-26
- Primary completion
- 2023-11-10
- Completion
- 2024-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meglumine antimonate | Other / unclassified | 20 mg/kg | Other |
| Subject | Miltefosine | Small molecule | 2.5 mg/kg | Oral |